MCED DNA blood tests market seen reaching $1.49 billion by 2030

The market for multicancer early detection DNA blood tests is projected to grow from $0.79 billion in 2025 to $1.49 billion by 2030, driven by demand for earlier cancer diagnosis and wider use of liquid biopsy, AI and genomic sequencing. North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - Multicancer early detection DNA blood tests aim to identify several cancers from one blood draw, which could shift cancer detection earlier and reduce reliance on invasive biopsy methods. - The market outlook points to sustained demand for non-invasive screening tools as cancer incidence rises worldwide. - The report also signals where diagnostic investment is flowing, with North America leading now and Asia-Pacific gaining speed.

What happened: - The Business Research Company released a report on the multicancer early detection DNA blood tests market covering 2026 to 2035. - The market is projected to rise from $0.79 billion in 2025 to $0.9 billion in 2026. - The report forecasts the market will reach $1.49 billion by 2030. - The forecast implies a 13.2% CAGR from 2025 to 2026 and a 13.4% CAGR through 2030. - The company also offered a free sample of the report. - The full report is available online.

The details: - MCED DNA blood tests analyze circulating tumor DNA and other biomarkers from a blood sample. - The tests combine genomic sequencing, artificial intelligence and bioinformatics to detect cancer signals at very early stages. - The report links market growth to rising cancer incidence and mortality, limitations of late-stage diagnosis, broader use of genomic sequencing in cancer research, growth in centralized diagnostic labs and greater awareness among healthcare practitioners. - Future growth is expected to be supported by liquid biopsy advances, AI-based genomic interpretation, wider use of personalized oncology screening, preventive healthcare programs and more investment in biomarker discovery and cancer genomics. - The market report highlights trends including liquid biopsy-based multi-cancer screening, ctDNA sequencing for non-invasive diagnostics, AI-driven biomarker interpretation, population-wide preventive screening and preference for minimally invasive blood tests. - The report says these tests can improve patient outcomes, support timely medical intervention and fit into precision oncology workflows. - The International Agency for Research on Cancer reported nearly 20 million new cancer cases and close to 10 million cancer deaths in 2022. - The agency projects 35 million new cancer cases annually by 2050, a 77% increase from 2022. - The Prevent Cancer Foundation reported a 9.3% increase in participation in preventive cancer screening programs in 2024 versus the prior year. - North America was the largest regional market in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America and the Middle East and Africa. - The 2026 report package includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics and updated graphics and tables.

Between the lines: - The report frames MCED testing as part of a broader shift toward preventive, data-driven cancer care rather than treatment after symptoms appear. - The combination of liquid biopsy, AI and genomics suggests the market is moving from lab innovation toward scaling diagnostic workflows. - The regional split suggests near-term commercial strength in mature health systems, with faster percentage growth coming from expanding screening investment elsewhere.

What's next: - The market’s next phase likely depends on how quickly screening programs, reimbursement and clinical adoption expand. - Ongoing biomarker discovery and genomic research may widen the range of cancers detectable from blood alone. - The report expects continued growth through 2030 as preventive healthcare and AI-assisted interpretation spread more widely.

The bottom line: - MCED DNA blood tests are moving from a niche diagnostic concept toward a sizable growth market, with demand fueled by earlier detection needs and a larger global cancer burden.